Boston Scientific Completes Acquisition of Sadra Medical

 

January 6, 2011

January 6, 2011 – Boston Scientific has completed its acquisition of transcatheter valve developer Sadra Medical.

The transaction follows the definitive merger agreement announced on Nov. 19. Under the terms of the agreement, Boston Scientific paid $193 million to acquire the remaining 86 percent of Sadra Medical's equity. Additional payments of up to $193 million are contingent upon achievement of specified regulatory and revenue-based criteria through 2016.

Sadra Medical is developing the first fully repositionable device for percutaneous aortic valve replacement to treat patients with severe aortic stenosis. The company recently completed a series of European feasibility studies for its Lotus Valve System, which consists of a stent-mounted tissue valve prosthesis and catheter delivery system for guidance and placement of the valve. The low-profile delivery system and introducer sheath are designed to enable accurate positioning, repositioning and retrieval at any time prior to release of the aortic valve implant.

For more information: www.bostonscientific.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.